We [93,99] analyzed the effects of TERT promoter mutations, BRAFV600E and age (cutoff 45 years) on survival of patients with thyroid cancer, and our results showed that the TERT promoter mutation was the only variable that independently predicted shorter disease-related survival (DRS) in PTC; the presence of TERT promoter mutations together with age > 45 was significantly associated with DRS in FTC. Here, TERT is linked to thyroid cancer.